scholarly journals Initiation and Single Dispensing in Cardiovascular and Insulin Medications: Prevalence and Explanatory Factors

Author(s):  
Carles Vilaplana-Carnerero ◽  
Ignacio Aznar-Lou ◽  
María Teresa Peñarrubia-María ◽  
Antoni Serrano-Blanco ◽  
Rita Fernández-Vergel ◽  
...  

Background: Adherence problems have negative effects on health, but there is little information on the magnitude of non-initiation and single dispensing. Objective: The aim of this study was to estimate the prevalence of non-initiation and single dispensation and identify associated predictive factors for the main treatments prescribed in Primary Care (PC) for cardiovascular disease (CVD) and diabetes. Methods: Cohort study with real-world data. Patients who received a first prescription (2013–2014) for insulins, platelet aggregation inhibitors, angiotensin-converting enzyme inhibitors (ACEI) or statins in Catalan PC were included. The prevalence of non-initiation and single dispensation was calculated. Factors that explained these behaviours were explored. Results: At three months, between 5.7% (ACEI) and 9.1% (antiplatelets) of patients did not initiate their treatment and between 10.6% (statins) and 18.4% (ACEI) filled a single prescription. Body mass index, previous CVD, place of origin and having a substitute prescriber, among others, influenced the risk of non-initiation and single dispensation. Conclusions: The prevalence of non-initiation and single dispensation of CVD medications and insulin prescribed in PC in is high. Patient and health-system factors, such as place of origin and type of prescriber, should be taken into consideration when prescribing new medications for CVD and diabetes.

2019 ◽  
Vol 129 (4) ◽  
pp. 148-151
Author(s):  
Tomasz Plech

AbstractInvasion of SARS-CoV-2 virus into human cells is mediated by the interaction of viral particles with a specific protein – angiotensin-converting enzyme 2 (ACE-2). Due to the involvement of ACE-2 in blood pressure regulation, there have appeared reports of possible negative effects of taking some cardiological drugs during coronavirus pandemic. Some hypotheses suggest an increased risk of SARS-CoV-2 infection and more severe clinical course of COVID-19 in patients treated with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. In the face of contradictory information regarding this question, several societies of cardiology and hypertension have issued clinical recommendations for patients treated with the above-mentioned drugs. These recommendations conclude that there are no unambiguous data that would support the hypothesis about the negative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on patients infected with SARS-CoV-2 virus. Therefore, it is highly recommended not to discontinue treatment in patients in whom these drugs lead to improvement in their clinical condition.


Sign in / Sign up

Export Citation Format

Share Document